Gene therapy applications of naked DNA constructs for genetic disorders have been limited because of lack of permanent transgene expression. This limitation, however, can be overcome by the Sleeping Beauty (SB) transposable element, which can achieve permanent transgene expression through genomic integration from plasmid DNA. To date, only one example of an in vivo gene therapy application of this system has been reported. In this report, we have further defined the activity of the SB transposon in vivo by analyzing the expression and integration of a fumarylacetoacetate hydrolase (FAH) transposon in FAH-deficient mice. In this model, stably corrected FAH ؉ hepatocytes are clonally selected and stable integration events can therefore be quantified and characterized at the molecular level. Herein, we demonstrate that SB-transposontransfected hepatocytes can support significant repopulation of the liver, resulting in long-lasting correction of the FAH-deficiency phenotype. A single, combined injection of an FAH-expressing transposon plasmid and a transposase expression construct resulted in stable FAH expression in ϳ1% of transfected hepatocytes. The average transposon copy number was determined to be ϳ1/diploid genome and expression was not silenced during serial transplantation. Molecular analysis indicated that high-efficiency DNA-mediated transposition into the mouse genome was strictly dependent on the expression of wild-type transposase.
INTRODUCTION
Transposon technology has been widely used as a molecular genetic tool in plants, bacteria, fungi, and insects [1] . For the experimental manipulation of vertebrate genomes, transposons from the Tc1/mariner superfamily have been used. Among these, the Sleeping Beauty (SB) element, a reconstructed version of the Tc1/mariner-like transposon from fish, is of particular interest [2] because it is able to transpose at a frequency superior to other elements of the same family [3] . The SB element transposes by a cut-and-paste mechanism that requires the binding of an element-encoded enzyme, the SB transposase, to short inverted-repeat (IR) sequences flanking the transposon [4] . These elements do not require host-specific factors for their activity in vitro [5, 6] and actively transpose from plasmid or genomic DNA into the chromosomal DNA of a wide variety of species such as bacteria [7] , mosquito [8] zebrafish [9, 10] , and chicken [11] and human cells [2, 12, 13] and mouse embryonic stem cells [14] . The SB element has been used in experimental manipulation of the mammalian genome mainly for germ-line transgenesis [15] and gene targeting [3, 16] . However, the SB transposon also holds promise for gene therapy applications, because it combines the capacity of stable integration with the use of simple plasmid DNA. In contrast to viral gene therapy vectors, naked DNA is easy and affordable to produce in large scales and much less immunogenic. Recent advances have made it possible to transfect several cell types efficiently with naked DNA in vivo, especially muscle and liver [17] . Nonetheless, there is currently only one published report of an in vivo gene therapy application of SB transposase [18] . Hemophilic mice deficient in factor IX (FIX Ϫ/Ϫ ) were injected with a two-plasmid SB system. One plasmid contained an expression cassette for the FIX cDNA surrounded by the SB-IR sequences and the second plasmid expressed the SB transposase. Mutant mice treated with these constructs had significantly improved clotting function, and transposase-dependent stable integration was demonstrated [18] . Because of the promise of the SB transposon revealed by these experiments, further characterization and testing in vivo were justified.
We chose to study DNA transposition in a mouse model of hereditary tyrosinemia type 1 (HT1) [19] , because of its unique advantages for the characterization of stable integration events in hepatocytes in vivo. HT1 is a lethal recessive liver disease caused by deficiency of fumarylacetoacetate hydrolase (FAH) [19] , the enzyme that catalyzes the last step in tyrosine degradation. In the HT1 liver, FAH-expressing hepatocytes display a strong proliferative advantage, grow clonally to form nodules, and repopulate the entire diseased liver mass [20, 21] . Because of this selective advantage, phenotypic recovery can be achieved by any technique that results in stable FAH expression, including cell transplantation therapy [22, 23] or virus-mediated gene transfer [20,22,24 -26] .
In this report, we took advantage of the characteristics of this model to study the SB transposon system further in vivo. We show that Sleeping Beauty can permanently transfect hepatocytes, resulting in phenotypic correction of murine HT1. The frequency of and nature of the integration events in mouse liver tissue were also determined.
RESULTS
We used the unique biology of the FAH knockout mouse to answer several questions regarding the behavior of the Sleeping Beauty gene transfer system in the liver in vivo. First, we wanted to know the rate of stable integration and gene expression. Second, we wished to determine whether gene expression was stable and could result in phenotypic rescue of the liver disease. Finally, the nature (copy number, sequences of integration sites) of the integration events was of interest.
Frequency of Stable Integration
Histochemical markers such as Escherichia coli lacZ or alkaline phosphatase can be utilized to determine the frequency of stable gene expression in liver [37, 38] . However, this method does not necessarily permit the determination of the frequency of vector integration, because stable gene expression can also be observed in the absence of integration [39] . Adeno-associated virus (AAV) vectors and even simple plasmid constructs can produce such long-term expression [25, 26] . In the FAH knockout liver, however, single FAH ϩ hepatocytes can selectively expand and form clonal nodules only if stable integration has occurred resulting in FAH expression in the daughters of the initially transfected hepatocytes [20, 25] . This characteristic can be exploited to determine rigorously the frequency with which a given gene transfer system results in both integration and stable gene expression. We injected FAH mutant mice hydrodynamically with transposon DNA while they were on 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). To measure the initial transfection frequency of hepatocytes, some animals were harvested and liver sections were stained for FAH expression on day 3 after injection. Microscopic examination showed that only ϳ0.5% of hepatocytes were FAH ϩ at this time-point (Table 1) . Few animals had higher levels (10%) consistent with previously reported results obtained with hydrodynamic injection [40] . The reason for this lower than expected initial transfection frequency is unclear, but may be related to the strain of mouse used here, since control injections in wild-type mice using lacZ-based reporters yielded frequencies of 5-12% (data not shown). Alternatively, FAH expression may still be relatively low on day 3 after injection, resulting in an underestimation of the true transfection frequency.
For measurement of the integration frequency, we injected four groups of FAH Ϫ/Ϫ mice with the following experimental plasmids and controls: group 1 (n ϭ 7), FAH transposon (pT-hFAH) plus the expression construct for wild-type transposase (pCMV-SB); group 2 (n ϭ 2), pThFAH plus the expression construct for mutant SB transposase (pCMV-mSB); group 3 (n ϭ 9), construct containing the FAH transposon and SB transposase in cis (pThFAH-SBcis); group 4 (n ϭ 4), pT-hFAH only. In groups 1 and 2, the previously determined [18] optimal ratio of 1 g of the transposase expression construct (pCMV-SB or pCMV-mSB) and 25 g of the transposable element pThFAH was used. On day 7 after plasmid injection NTBC was discontinued to permit the development of liver disease and formation of hepatocyte nodules. All animals were harvested on day 25 following injection. The frequencies of FAH ϩ nodules and FAH ϩ single hepatocytes were quantitatively determined and the results are summarized in Fig. 1 and Table 2 .
In liver sections from group 1 (mice treated with wildtype transposase in trans), the average absolute frequency of FAH ϩ nodules was 7.3 Ϯ 9.8 ϫ 10 Ϫ5 (1/13,700). The nodule frequency ranged from a maximum of 1/3600 in the best mouse to 1/165,000 in the worst.
The absolute frequency of FAH ϩ nodules only as a measurement of stable integration is the most conservative and is probably an underestimation. However, it is likely that several single FAH ϩ hepatocytes on day 25 are also products of chromosomal integration. This view is supported by the high frequency of single FAH ϩ hepatocytes in the group treated with the wild-type transposase and the absence of any single cells in groups 3 and 4 that We also calculated the integration efficiency estimates considering the initial transfection efficiency after hydrodynamic injection and after correction for the sampling effects caused by the nodule size. The precise initial transfection frequencies for the animals harvested on day 25 after injection cannot be measured, but have been estimated based on control animals harvested 3 days after injection. We performed calculations for both the observed average transfection frequency of 0.5% obtained with FAH expression constructs (see Table 1 ) and the maximal observed transfection efficiency of 10%. These results are summarized in Table 3 .
In group 1, injected with the FAH transposon and wild-type SB transposase, the best estimate (using the actual observed initial transfection frequency) of the corrected integration frequency was an average of 4% (1/25) . This number is very close to the estimates of Yant et al. [18] . As expected, the frequency of integration in each of the control groups was much lower.
Phenotypic Rescue
The formation of FAH ϩ nodules described above clearly indicated that SB resulted in stable integration and expression of the transgene. We wished also to determine whether transposon-based gene expression was sufficiently high enough to cure the tyrosinemia, whether it was stable long-term, and whether any adverse events (for example, tumor formation) were detectable in transposon-transfected cells. Therefore, to analyze the therapeutic potential of the FAH-SB transposon system, we injected a total of 26 FAH Ϫ/Ϫ mice with pT-hFAH in combination with either pCMV-SB (n ϭ 13) or pCMVmSB (n ϭ 13). On day 7 after injection, animals were taken off NTBC to start the selection process. Between days 14 and 30, mice of both groups lost almost 30% of their initial body weight and some died from liver failure ( Fig. 2A) . To reduce the observed mortality NTBC treatment was subsequently reestablished at day 30 for 2 weeks (Fig. 2B) . At the end of this recovery period, the mice were again taken off-NTBC (Fig. 2B ). Sixty-two percent (8/13) of the mice treated with pT-hFAH and pCMV-SB survived up to 90 days off NTBC (the length of the study). These survival kinetics are consistent with the relatively low absolute integration frequency of Ͻ1/1000 shown in Ta- with standard deviation are given. In addition, the minimum (Min, worst animal), median, and maximal (Max, best animal) frequencies in each group are shown. Two-tailed t tests showed statistically significant differences between the means in groups 1 and 3. Differences between 1 and 2 were not significant because of the low n in group 2. The integration frequencies are given for the different plasmids. The calculations were made assuming initial transfection efficiencies of either 0.5 or 10% and counting either FAH ϩ nodules alone or both nodules and single cells as integration events. Averages with standard deviation are given. In addition, the minimum (Min, worst animal), median, and maximal (Max, best animal) frequencies in each group are shown. ble 2. Interestingly, 3/13 (23%) mice treated with pThFAH and pCMV-mSB also survived ( Fig. 2A) . This finding agrees with our previously reported results that absolute correction frequencies of as low as 1/500,000 can result in phenotypic rescue of FAH mutant mice [22, 33] . All longterm survivors appeared healthy and gained up to 120% of their original body-weight (Fig. 2B ). Hepatic functions were in the normal range (Table 4) . Liver sections were immunostained to detect FAH ϩ cells and revealed large areas of healthy FAH ϩ hepatocytes (see Fig. 1C ). These findings demonstrated that the frequency of stable transposon integration following a single injection of the wildtype SB transposon system was high enough to rescue the lethal FAH Ϫ/Ϫ phenotype (untreated mice die between 20 and 45 days after NTBC deprivation). However, stable integration and gene expression were observed even in the absence of wild-type transposase activity in a small number of mice.
To understand the differences between the groups treated with pT-hFAH and active or mutant transposase better, we performed a quantitative time course. Liver samples from mice from the two different groups (groups 1 and 2) were harvested at days 3 and 90 after stopping NTBC (n ϭ 3 mice/time point). FAH ϩ hepatocytes were identified by immunohistology. On day 3 after injection both experimental groups had the same number of FAH ϩ
FIG. 2. Survival curves and weight gain of treated mice. (A) A total of 26 FAH
Ϫ/Ϫ mice were injected with pT-hFAH in combination with either wild-type transposase (wt) or mutant transposase (m). Survival was better in the animals injected with wild-type transposase. In both groups, some animals survived for more than 4 months off NTBC (the end of the experiment). In contrast, untreated controls died by 7 weeks after NTBS withdrawal. (B) Body weight variation in surviving mice. On day 3 after injection the animals were taken off NTBC. At day 30, weight loss ranged between 10 and 30%. To reduce the mortality, mice were then treated with NTBC for 2 weeks. During this period all survivors gained the original body weight. At day 45 after injection the animals were again taken off NTBC. During this second period of selection all mice gained up to 120% of the original body weight and appeared healthy.
hepatocytes (0.5%, see Table 1 ) and no FAH ϩ nodules were identified. However, the level of repopulation was markedly different on day 90. Higher levels of repopulation (60 Ϯ 12% vs 9 Ϯ 7%) were observed when the construct expressing wild-type transposase was used. The higher death rate in mice injected with the mutant transposase construct also suggested that the low level of gene transfer achieved was insufficient for survival in most animals.
We documented the stability of the gene transfer further by performing serial transplantation experiments. Long-term survivors (Ͼ90 days) treated with pT-hFAH ϩ pCMV-SB were used as hepatocyte donors for two serial transplantation experiments (n ϭ 4) into naive FAH Ϫ/Ϫ recipient mice (three each per donor). All serially transplanted FAH mutant mice survived NTBC withdrawal and displayed normal health (no weight loss). Secondary recipients that had survived Ͼ90 days off NTBC were then used as donors for a second round of transplantation (transplanted with 10,000 or 500,000 hepatocytes) and again, all FAH Ϫ/Ϫ tertiary recipients were fully rescued (see Table 4 ). Importantly, no liver tumors were observed in any of the serial transplant recipients and the histology of the repopulating cells was normal (data not shown). The expansion of the initially transfected hepatocytes (1/1000 cells) to ϳ60% of the liver mass (3 ϫ 10 7 cells) and two rounds of serial transplantation would require at least 30 rounds of cell doubling. Therefore, transposonmediated FAH expression was remarkably stable and not associated with an increased incidence of transformation.
Integration Site Analysis
We also determined the nature of the transposon integration sites. Southern blot analysis of DNA from highly repopulated livers (Ͼ60% by immunohistochemistry) derived from long-term survivors (5 months off NTBC) was used to determine the copy number of integrated transposons and to ascertain whether the integration had occurred by transposition or by random integration. In the pT-hFAH plasmid PstI restriction sites are located immediately adjacent to the inverted terminal repeat of the transposable element (see Fig. 3 ). This site is therefore expected to be lost during proper transposase-mediated integration, but preserved during most random insertion events. A second digestion with SacI was used to distinguish between episomal and randomly integrated transposons. In addition, a constant transposon-specific and integration-independent band was compared to an internal, mouse genomic locus to measure the transposon copy number. Maps of the Southern blot strategy are given in Fig. 3A and the results are shown in Table 5 and Figs. 3B and 3C. In mice injected with pT-hFAH and the wild-type transposase, virtually all integration sites (Ͼ98%) had lost the flanking PstI site, which indicates transposase-mediated integration. This was confirmed by the rescue of several integration sites via inverse PCR. The majority of integration sites (6/7) displayed the canonical TA dinucleotide at the expected location for SB-mediated integration ( Table 6) . Results of BLASTn analyses of the genomic portion suggest that the integration occurred at random locations in the genome. Importantly, the average copy number of FAH-positive cells was ϳ1/genome equivalent. The average corrected copy number (Table 5) was 0.78, consistent with the degree of repopulation observed by immunohistochemistry (Ͼ60%, but Ͻ100%). Therefore, each gene-transfected cell likely underwent only a single transposition event. Moreover, the lack of multiple integration sites and the low copy number indicate that most transposition events resulted in long-term FAH expression in vivo.
In contrast to the animals treated with wild-type SB, ϳ50% of the integration events (0.19/0.38, Table 5 ) in the mutant SB group resulted in retention of the PstI site, consistent with random integration. Although ϳ50% of the integration events did not result in loss of the PstI site, it is important to note that this does not necessarily signify integration by proper transposition. A breakpoint for random integration anywhere between the end of the FAH coding region and the PstI site would also result in loss of the 1.6-kb fragment. The mutant transposase used has no transposition activity in vitro [18] , making it very unlikely that the loss of the 1.6-kb fragment is due to transposase-mediated integration. BU (mg/dl) 0 (6) 0 (3) 0 (5) 0 (4) 0.5 (6) 0 (7) CREAT (mg/L) 0.13 Ϯ 0.07 (6) ND 0.20 (5) 0.18 Ϯ 0.05 (4) 1.5 Ϯ 0.2 (9) 0.2 Ϯ 0.1 (7) Serum levels of alanine aminotransferase (ALT), conjugated bilirubin (BC), unconjugated bilirubin (BU), and creatinine (CREAT) were measured in mice treated with different experimental protocols. Animals were analyzed while either on NTBC or off NTBC for 6 weeks. Mice treated with wild-type transposase were analyzed during the first round of repopulation or after serial transplantation (tertiary recipients). ND, not determined.
DISCUSSION
Most of the work aimed at treating genetic diseases, including inborn errors of metabolism affecting the liver, by gene therapy has focused on the use of viral vectors such retroviral, adenoviral, and adeno-associated virus vectors [41] . Nonviral gene transfer methods have received less attention because it was thought that naked DNA constructs lacked the ability to result in stable chromosomal integration and persistent gene expression. Recently, however, several systems have been developed that allow 3, 4 , 7, and 9) or mutated (2) SB was used.
stable integration of plasmid constructs into chromosomal DNA by either transposition [2] or recombination [42] . The Tc1-like transposon Sleeping Beauty has shown particular promise and has already been applied for in vivo gene therapy in mouse liver [18] . In this original study, high levels of stable factor IX expression were achieved and it was estimated that the absolute frequency of stable integration approached 2% with a single hydrodynamic injection of both transposon and transposase plasmids. Despite this relatively high efficiency, the stably transfected cells represented only a small portion of the total liver and thus molecular studies regarding the nature of the integration events were limited. In this report, we have further studied the potential utility of this transposon system in vivo using the FAH knockout mouse model. This model was chosen because it permits selection of stably transfected hepatocytes, thus facilitating analyses of transposon-corrected cells by Southern blot and histological methods.
The absolute frequency of transposase-mediated FAH gene transfer observed here was surprisingly low at only 2.6 Ϯ 3.1 ϫ 10 Ϫ4 (1/3800). However, this observation is most likely explained by the low initial transfection efficiencies achieved by hydrodynamic injection in FAH mutant mice. We have found that the frequencies are typically less than 1%, i.e., 10-to 20-fold lower than reported by the literature [40] and found by us in other strains of mice. The precise reason for this atypical behavior is currently unknown, but it is likely that the transient hepatic injury induced by hydrodynamic transfection is more severe in FAH knockout mice. When the integration efficiency was corrected for transfection efficiency, we found that ϳ4% of transfected hepatocytes had undergone a transposase-mediated integration event and expressed FAH. If only nodules were counted as stable integration events, the average integration frequency still was lower at 0.5% than that previously reported [18] but still significant. The FAH expression was stable and led to the phenotypic correction of the metabolic liver disease and secondary renal damage. Transposon-modified hepatocytes could be serially transplanted and never formed tumors despite at least 30 cell doublings. Thus, the Sleeping Beauty transposon/transposase does not appear to be associated with the induction of genomic instability. Furthermore, our results indicated that the inclusion of the transposon and transposase on the same plasmid (cisconstruct) resulted in much lower gene transfer frequencies. This was not unexpected, because it had previously been shown that the optimal ratio of transposase to transposon is ϳ1:25 when the transposase expression is driven by the CMV promoter [18] . The level of transposase expression in the transfected hepatocytes was likely too high. Therefore, it might be necessary to test additional cis-acting constructs utilizing weaker promoters in future in vivo experiments to maximize the power of this integrative nonviral system fully.
Southern blot analysis permitted the accurate quantitation of the copy number and the analysis of the integration events. Importantly, the copy number of FAHexpressing transposon per genome was close to 1. This indicates that virtually all transposase-mediated integration events were "productive" and associated with FAH gene expression. This is in contrast to some other gene transfer systems, most notably AAV, which results in multiple copies per hepatocyte [43] . Transposition may therefore occur into regions of the genome that are transcriptionally active and hence accessible. In the case of the wild-type transposase, Ͼ95% of all integration events resulted in the loss of restriction sites directly adjacent to the inverted repeats, consistent with the established transposition mechanism. In contrast, many integrations found in mice injected with mutated transposase showed evidence for retention of parts of the plasmid backbone, suggesting random integration events. In addition, the absolute frequency of integration was much lower in animals injected with mutated transposase.
Overall, the results obtained here confirm the therapeutic potential of the Sleeping Beauty transposon/transposase system for in vivo gene therapy application in the liver. Despite its promise, however, the low absolute gene transfer efficiency seen in our experiments illustrates that the technology must be improved before successful clinical application can be contemplated. There are two major rate-limiting steps. First, DNA uptake by hepatocytes in vivo is not very efficient, even with the hydrodynamic method of injection. Although hydrodynamic injection works reasonably well in rodents, it is a much too traumatic procedure to be considered for use in humans. Safer methods of delivery including liposomes and polyethyleneimine-complexed DNA may solve the problem in the future [44, 45] . Another approach is to incorporate the Sleeping Beauty system into a viral vector with hepatotropism. In fact, such a vector was recently tested successfully in vivo [46] .
The second rate-limiting step is the actual integration once the DNA has entered the cell. Once a hepatocyte has taken up the naked DNA, transposition is relatively efficient (1-5%), even with the currently used two-plasmid system. Nonetheless, improved constructs that contain the transposable element and the transposase in cis in the same plasmid and express optimal levels of transposase may further enhance this efficiency. It is also possible that the Sleeping Beauty transposase enzyme could be improved to catalyze integration more efficiently, perhaps by in vitro evolution [47] .
The use of naked DNA for the treatment of genetic liver diseases has several obvious potential advantages over more conventional gene transfer vectors. These include the ability to generate the required plasmids in large quantities at reasonable cost and the low immunogenicity of naked DNA, which should allow multiple rounds of readministration. The main rate-limiting step for future in vivo use of this method appears to be the uptake of DNA into hepatocytes. We are hopeful that the now clearly documented potential for stable gene transfer with plasmid DNA with energize the search for safe methods to achieve this goal.
MATERIALS AND METHODS
Vector construction. The plasmids pCMV-SB (expressing the SB transposase under the control of the CMV promoter) and pCMV-mSB (encoding a mutated, nonfunctional transposase) have been reported previously [18] . The full-length human FAH cDNA contained in phFAFFA2 (1.4 kb) [27] was cloned into a blunted EcoRI site of the expression plasmid pCD-SR␣ [28] . The resulting plasmid pCD-SR␣hFAH expresses the FAH enzyme under the transcriptional control of the SR␣ promoter and contains an SV40 polyadenylation sequence (entire expression cassette 3.46 kb). This cassette was released by digestion with SalI and cloned into pT-MCS [18] at the XhoI site between the IR sequences. The resulting 7-kb plasmid pThFAH contained a 4.38-kb transposon.
A synthetic oligonucleotide linker containing the restriction sites XhoI-NarI-XhoI was cloned into the SalI restriction site adjacent to the 3Ј IR sequence. In the resulting plasmid, the hFAH transposon was now contained within a 5-kb NarI fragment, which was cloned into the NarI restriction site of the plasmid pCMV-SB. The resulting construct, pT-hFAHSBcis, contains both the hFAH transposon and the CMV-promoter-driven transposase expression cassette in cis.
Animal husbandry, transposon injection, and hepatocyte selection. Sixto eight-week-old mice of the FAH ⌬exon5 strain [19] were treated according to the NIH Guidelines for Animal Care and with approval of the institutional animal care and utilization committee of the Oregon Health and Sciences University. Plasmid DNA diluted in 0.9% NaCl (2 ml) was hydrodynamically injected into the tail vein over 5-8 s as previously described [29, 30] . All FAH ⌬exon5 breeders and mutant animals were treated with NTBC containing water at a concentration of 7.5 mg/L (provided by S. Lindstedt, Gothenborg, Sweden) for a week after injection [31] . To allow the expansion of the FAH-expressing hepatocytes, animals were then taken off the protective drug and the body weight was measured weekly. NTBC therapy was reinstated for 1 week whenever animals lost more than of 25% their pretreatment weight. After weight restoration, NTBC was again discontinued.
Hepatocyte transplantation. Transposon-injected FAH
Ϫ/Ϫ mice that survived for more than 3 months off NTBC were used as hepatocyte donors for serial transplantation experiments as previously described [32] . During the first round of serial transplantation 500,000 hepatocytes were injected into the spleen of isogenic FAH Ϫ/Ϫ mice. For all subsequent rounds of transplantation we used either 10,000 or 500,000 hepatocytes.
Liver function tests. Animals were sacrificed by decapitation and blood was collected in Microtainer plasma separator tubes with lithium heparin (Becton-Dickinson Vacutainer Systems, Franklin Lakes, NJ). After brief centrifugation the plasma was frozen at Ϫ80°C. Twenty microliters of plasma was mixed with 80 l of a 7% (w/v) bovine serum albumin solution and assayed for aspartate serine aminotransferase, bilirubin, and creatinine levels using a Kodak Ektachem 700 chemistry analyzer (Eastman Kodak, Rochester, NY).
Histology and immunohistology. Liver tissues fixed in 10% phosphatebuffered formalin, pH 7.4, were dehydrated in 100% ethanol and embedded in paraffin wax at 58°C. Four-micrometer sections were rehydrated and stained with hematoxylin and eosin and with a polyclonal rabbit antibody against rat FAH (kindly provided by Robert Tanguay, University of Laval, Quebec, Canada). The antibody was diluted in PBS, pH 7.4, and applied at concentrations of 1:300,000 at 37°C for 30 min. Endogenous peroxidase activity was blocked with 3% H 2 O 2 and methanol. Avidin and biotin pretreatment was used to prevent endogenous staining. The secondary antibody was biotinylated goat anti-rabbit IgG used at 1:250 dilution (BA-1000; Vector Laboratories, Burlingame, CA). Color development was performed with the AEC detection kit (Cat. No. 250-020; Ventana Medical Systems, Tucson, AZ).
Determination of the integration efficiency. FAH
Ϫ/Ϫ mice were injected via the tail vein with different combinations of plasmids (described under Results). After 25 days of in vivo selection (i.e., no NTBC), the liver was harvested and sections of at least 0.7 cm 2 were analyzed by FAH immunohistology for the presence of FAH ϩ hepatocytes using a Leica microscope DM RX (Leica Microsystems, Bannockburn, IL). FAH ϩ clusters (two or more cells) and FAH ϩ single hepatocytes present in a given histological section were counted and noted separately. The precise surface area of each section was measured by scanning the glass slides along with a size standard using a Microtec 2 scanner at a resolution of 300 dpi. Adobe PhotoShop 5.02 software was then used to select and count the pixels corresponding to the liver sections. FAH mutant liver contains 186,000 hepatocytes/cm 2 [33] . Since clonal hepatocyte nodules are larger than single hepatocytes, they will be more readily detected in a two-dimensional section. The correction factor required to adjust calculations of nodule frequency was calculated as previously described [33] .
We performed the following calculations to produce the numbers shown in Tables 1-3 . The initial transfection frequency (Table 1) was determined by counting the number of FAH ϩ hepatocytes on day 3 after injection and dividing this number by the total number of hepatocytes scored. The absolute frequencies of FAH ϩ single cells and clusters (Table 2 ) represent the raw, uncorrected number of events divided by the total number of hepatocytes in the section. The mean, median, and standard deviation given in the table were calculated using Prism 3 software (GraphPad). The corrected integration frequencies (Table 3) represent data from Table 2 that have been adjusted in two ways. First, the absolute numbers were corrected for the estimated initial transfection frequency. Calculations were made for the observed average transfection frequency (0.5%) as well as the highest observed frequency (10%). In addition, the nodule frequencies in Table 3 were corrected for nodule size. The larger the nodules, the lower the estimated frequency [33] .
Southern blot analysis. For Southern blots, liver DNA was isolated from liver freshly obtained or from liver frozen at Ϫ80°C. At least 350 mg of tissue (ϳ1/3 of entire liver mass) was used for DNA isolation. Capillary transfer and hybridizations were performed according to standard protocols [34] .
For quantification of the transposon copy number, liver DNA was digested with PstI or SacI (Roche, Indianapolis, IN) and probed with a 1.4-kb EcoRI fragment isolated from phFAFFA2 containing the entire coding sequence of the human FAH cDNA. As an internal control, we used a 200-bp fragment from a genomic region of the mouse maleylacetoacetate isomerase (MAAI) gene [35] . The intensity of the FAH bands was normalized to the relative intensity of the corresponding MAAI control band and quantified by Phosphoimager analysis. Calculations for copy number determination were performed as described previously [36] .
Inverse PCR. All PCRs were performed as described in standard protocols [34] . Mouse liver genomic DNA (2 g) from repopulated mice was digested with Sau3AI (Fermentas, Hanover, MD) and diluted to 100 l and then different amounts of digested DNA (1 g, 100 ng, or 10 ng) were circularized with a standard ligation reaction at a final volume of 100 l. Selfligated template DNA was then used for the first round of PCR amplification with oligonucleotide pairs designed for the left end of the transposon sequences (MG1094, AAACGAGTTTTAATGACTCCAAC, and MG1118, AGGCAGGCAGAAGTATGC). The cycling conditions were 94°C for 45 s, 60°C for 45 s, 72°C for 4 min repeated for 30 cycles and followed by 72°C for 10 min. A second round of amplification was performed using a nested pair of oligonucleotide primers: MG1096, 5Ј-AAAGATCGAGTTTTAAT-GACTCCAACTTAA, and MG1119, 5Ј-AGGCAGAAGTATGCAAAGC. PCR products were separated on a 3% agarose gel and the PCR specificity was determined by Southern blot hybridization using another nested oligonucleotide (MG1100, 5Ј-TGTAAACTTCCGACTTCAACT). All reactions displayed positive signals (data not shown).
Inverse PCR products were cloned into the pCRII vector (Invitrogen, Carlsbad, CA), sequenced, and analyzed by BLASTn homology database searches. The significance score for the indicated homologies was 1 ϫ 10 Ϫ20 .
